| 韩 尚,纪雅玲,王 浩,张 瑶,汪海岩.信迪利单抗联合安罗替尼对晚期非小细胞肺癌患者血清肿瘤标志物、血管生成因子和NLR、PLR、LMR的影响[J].,2024,(19):3676-3678 |
| 信迪利单抗联合安罗替尼对晚期非小细胞肺癌患者血清肿瘤标志物、血管生成因子和NLR、PLR、LMR的影响 |
| Effect of Sintilimab Combined with Anlotinib on Serum Tumor Markers, Angiogenesis Factors, NLR, PLR and LMR in Patients with Advanced Non-Small Cell Lung Cancer |
| 投稿时间：2024-02-11 修订日期：2024-02-28 |
| DOI：10.13241/j.cnki.pmb.2024.19.019 |
| 中文关键词: 信迪利单抗 安罗替尼 晚期非小细胞肺癌 肿瘤标志物 血管生成因子 NLR PLR LMR |
| 英文关键词: Sintilimab Anlotinib Advanced non-small cell lung cancer Tumor markers Angiogenesis factors NLR PLR LMR |
| 基金项目:江苏省卫健委高层次卫生人才"六个一工程"拔尖人才科研项目（LGY2020006） |
|
| 摘要点击次数: 20 |
| 全文下载次数: 9 |
| 中文摘要: |
| 摘要 目的：探讨安罗替尼和信迪利单抗联合对晚期非小细胞肺癌（NSCLC）患者血清血管生成因子、肿瘤标志物和血小板/淋巴细胞比值（PLR）、中性粒细胞/淋巴细胞比值（NLR）、淋巴细胞/单核细胞比值（LMR）的影响。方法：根据随机数字表法将84例晚期NSCLC患者分为对照组（42例，安罗替尼治疗）和研究组（42例，信迪利单抗联合安罗替尼治疗）。对比两组疗效、血清肿瘤标志物[细胞角质蛋白19片段抗原21-1（CYFRA21-1）、糖类抗原125（CA125）和癌胚抗原（CEA）]、血管生成因子[血管内皮生长因子（VEGF）、碱性成纤维细胞生长因子（bFGF）]、NLR、PLR、LMR，观察两组不良反应发生率。结果：与对照组治疗后相比，研究组的客观缓解率、疾病控制率、LMR更高，VEGF、bFGF、CA125、CYFRA21-1、CEA、NLR、PLR更低（P<0.05）。两组不良反应发生率组间对比未见差异（P>0.05）。结论：联合应用安罗替尼以及信迪利单抗治疗晚期NSCLC患者，可降低肿瘤标志物水平、抑制NSCLC血管生成、减轻炎症反应。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effects of anlotinib combined with sintilimab on serum angiogenesis factors, tumor markers, platelet/lymphocyte ratio (PLR), neutrophil/lymphocyte ratio (NLR) and lymphocyte/monocyte ratio (LMR) in advanced non-small cell lung cancer (NSCLC) patients. Methods: 84 advanced NSCLC patients were divided into control group (42 cases, treated with anlotinib) and study group (42 cases, treated with sintilizumab combined with anlotinib) according to the random number table method.The efficacy, serum tumor markers [cytokeratin 19 fragment antigen 21-1 (CYFRA21-1), carbohydrate antigen 125 (CA125) and carcinoembryonic antigen (CEA)], angiogenesis factors [vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF)], NLR, PLR, LMR were compared between two groups, the incidence of adverse reactions was observed. Results: Compared with control group post-treatment, the objective remission rate, disease control rate and LMR in study group were higher, and VEGF, bFGF, CA125, CYFRA21-1, CEA, NLR and PLR were lower(P<0.05). There was no difference in the total incidence of adverse reactions between two groups(P>0.05). Conclusion: Combined use of anlotinib and Sintilimab in the treatment of advanced NSCLC patients, which can reduce the level of tumor markers, inhibit NSCLC angiogenesis, and reduce inflammatory response. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
